CAS: 470-37-1; (1R,2R,2Ar,3As,3Br,5Ar,7S,9As,9Bs,11Ar)-7-Hydroxy-9A,11A-Dimethyl-1-(2-Oxo-2H-Pyran-5-yl)Hexadecahydronaphtho[1',2':6,7]Indeno[1,7A-B]Oxiren-2-Yl Acetate
该化合物是一种自然形成的化合物,被归类为bufadienolide,是一种血清甘油,主要来自某些蛤虫的皮肤,特别是布福根乌斯的青蛙,该化合物展示了一系列生物活动,包括可能影响心脏肌肉收缩的心血管效应;Cinobufagin研究其潜在的治疗应用,特别是在传统医学中,据认为它具有抗癌,抗炎和免疫性肿瘤特性;该物质的特点是其复杂的分子结构,其中包括一种类固醇骨和有助于其生物活动的具体功能组;然而,由于它的强大影响,该物质还可能具有毒性,需要仔细考虑其使用;研究继续探索其行动机制和可能的临床应用机制,同时解决安全和效率问题;与许多自然化合物一样,对传统和现代医学环境都十分关注该物质的药理学特征.
- 英文名称(1R,2R,2Ar,3As,3Br,5Ar,7S,9As,9Bs,11Ar)-7-Hydroxy-9A,11A-Dimethyl-1-(2-Oxo-2H-Pyran-5-yl)Hexadecahydronaphtho[1',2':6,7]Indeno[1,7A-B]Oxiren-2-Yl Acetate
- 中文名称蟾酥
- IUPAC名称(1R,2R,2aR,3aS,3bR,5aR,7S,9aS,9bS,11aR)-7-hydroxy-9a,11a-dimethyl-1-(2-oxo-2H-pyran-5-yl)hexadecahydronaphtho[1',2':6,7]indeno[1,7a-b]oxiren-2-yl acetate
- 其它别名5b,20(22)-Bufadienolide-3b,16b-diol-14,15b-epoxy 16-acetate
- CAS编号470-37-1
- MFCD编号:MFCD00056825
- EINECS号:636-927-8
- FDA UNII编号:T9PSN4R8IR
- 分子式:C26H34O6分子量:442.55
- 产品CID: 1465068
- 产品分类生物化工 → 提取物
物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS06;
注释: Skull and crossbones - 危险类别急性毒性 类别1(吸入)
急性毒性 类别2(经皮)
急性毒性 类别2(经口)
急性毒性 类别2(吸入) - 警示词Danger(危险)
- 危险描述H330 |吸入致命.
H310 |皮肤接触致命.
H300 |吞咽致命. - 防范说明P260-P264-P280-P284-P302+P350-P310
- 危险等级6.1(a)
- UN编号UN 2811 6.1/PG 1
- 危险品标志Xi,T+,Xn
- 包装等级II
- 安全声明26-36-45-36/37/39-22-24/25
- 危险类别码36/37/38-26/27/28-42/43-20/22
- WGK Germany3
欧盟法规
ECHA物质C&L通报上下游产品
CAS号1108-68-5 华蟾毒它灵合成工艺路线路线简述
📜在 吡啶,4-二甲氨基吡啶,氟化氢吡啶体系中,用 四氢呋喃 作为反应溶剂,化学反应 20.25H,反应生成 蟾酥
参考文献:通过后期单线态氧氧化/重排方法合成蟾蜍二烯内酯华蟾素精
标题:通过后期单线态氧氧化/重排方法合成蟾蜍二烯内酯华蟾素精
摘要:该手稿描述了华蟾蜍精(蟾蜍二烯内酯家族的一种天然类固醇)的简明合成,其由容易获得的脱氢表雄酮(dhea)及其衍生自 3-表雄酮的 α5-差向异构体组成.该合成的特点是使用光化学区域选择性单线态氧 [4 + 2] 环加成,将 17β-吡喃酮部分与 14β,15β-环氧化物和 16β-乙酰氧基方便地安装在一起,然后通过 Cotpp 促进的原位内过氧化物重排来提供 14β,16β-双环氧化物,产率 64%,Dr 为 1.6:1 这种 β,β-双环氧化物中间体随后进行区域选择性三氟甲磺酸钪 (Iii) 催化的 House-Meinwald 重排,以建立 17β-构型.华蟾素的合成经过12步(lls)实现,总产率为7.6%,我们证明它可以作为华蟾素类似物(如华蟾素5α-差向异构体)后续药物化学探索的平台.
DOI:10.1021/acs.Orglett.4C00625
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2024109742-A1
优先权日:2022-11-21
标题:Method for efficiently synthesizing bufadienolides and derivatives thereof
发明人：LIN GUOQIANG; YE WENBO; ZHAO QUNFEI; ZHANG JIANGE; HE QINGLI; WANG CHAO; YU SHAOPENG
权利人:UNIV SHANGHAI TRADITIONAL CHINESE MEDICINE
摘要:Disclosed in the present invention is a method for efficiently synthesizing bufadienolides and derivatives thereof. By starting from cheap and easily-available androstenedione 4-AD, the method performs bio-enzyme oxidization on same to obtain 14-α-hydroxy-androstane-17-one compounds, then completes loading of E-ring pyrone by using chemical conversion without any protective group so as to obtain a key intermediate, and achieves synthesis of bufadienolides by starting from the key intermediate. The method synthesizes resibufogenin in just eight operation steps, has simple and short route, simple operations and large reaction scale, can be used for large-scale preparation of such natural products, and has use prospects in industrial production.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Cao Y, Yu L, Dai G, Zhang S, Zhang Z, Gao T, Guo W. Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling. Eur J Pharmacol. 2017 Jan 5;794:77-84. doi: 10.1016/j.ejphar.2016.11.016. Epub 2016 Nov 12. doi: 10.3892/or.2016.4782. Epub 2016 Apr 28.
3: Chen T, Yuan S, Wan XN, Zhan L, Yu XQ, Zeng JH, Li H, Zhang W, Hu XY, Ye YF, Hu W. Chinese herb cinobufagin-reduced cancer pain is associated with increased peripheral opioids by invaded CD3/4/8 lymphocytes. Oncotarget. 2017 Feb 14;8(7):11425-11441. doi: 10.18632/oncotarget.14005.
4: Cao F, Kang X, Wang L. [Effects of cinobufagin on apoptosis in U-2OS osteosarcomas cells]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2014 Mar;28(3):349-53. Chinese. Chinese. doi: 10.1016/j.toxlet.2012.11.006. Epub 2012 Nov 16. doi: 10.1111/j.1476-5381.2011.01671.x.
合成参考文献
摘要:Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology., 86(269), 1985 []
摘要:Pharmaceutica Acta Helvetiae., 24(222), 1949
参考文献:10.1007/s00216-018-1097-4
摘要:Ren W, Han L, Luo M, Bian B, Guan M, Yang H, Han C, Li N, Li T, Li S, Zhang Y, Zhao Z, Zhao H. Multi-component identification and target cell-based screening of potential bioactive compounds in toad venom by UPLC coupled with high-resolution LTQ-Orbitrap MS and high-sensitivity Qtrap MS. Analytical and Bioanalytical Chemistry. 2018 Apr 28;410(18):4419–35. doi: 10.1007/s00216-018-1097-4.
摘要:Yue BB. [High dose cinobufocini in attenuation and treatment of infection and granulocytopenia during combined chemotherapy of malignant blood diseases]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992 Mar;12(3):145–7, 131.
参考文献:10.1021/jm0102811
摘要:Farr CD, Tabet MR, Ball WJ, Fishwild DM, Wang X, Nair AC, Welsh WJ. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J Med Chem. 2002 Jul 18;45(15):3257–70. doi: 10.1021/jm0102811.
📝 需求与反馈
尽可能描述清楚需求与问题信息
